Radiation therapy for melanoma brain metastases: a systematic review

John F. Thompson1,2,3, Gabrielle J. Williams1,2, Angela M. Hong1,2,4

1 Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia
2 Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
3 Royal Prince Alfred Hospital, Sydney, NSW, Australia
4 Chris O’Brien Lifehouse, Sydney, NSW, Australia

Radiol Oncol 2022; 56(3): 267-284.

Received 25 May 2022
Accepted 17 June 2022

Correspondence to: Prof. John Thompson, Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
E-mail: John.thompson@melanoma.org.au

Disclosure: JFT is the recipient of an Australian National Health and Medical Research Council Program Grant (APP1093017). He has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, and travel and conference support from GSK, Provectus Inc and Novartis. AMH has received honoraria for advisory board participation from Bayer and Oncobeta. GJW has nothing to disclose.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Background. Radiation therapy (RT) for melanoma brain metastases, delivered either as whole brain radiation therapy (WBRT) or as stereotactic radiosurgery (SRS), is an established component of treatment for this condition. However, evidence allowing comparison of the outcomes, advantages and disadvantages of the two RT modalities is scant, with very few randomised controlled trials having been conducted. This has led to considerable uncertainty and inconsistent guideline recommendations. The present systematic review identified 112 studies reporting outcomes for patients with melanoma brain metastases treated with RT. Three were randomised controlled trials but only one was of sufficient size to be considered informative. Most of the evidence was from non-randomised studies, either specific treatment series or disease cohorts. Criteria for determining treatment choice were reported in only 32 studies and the quality of these studies was variable. From the time of diagnosis of brain metastasis, the median survival after WBRT alone was 3.5 months (IQR 2.4–4.0 months) and for SRS alone it was 7.5 months (IQR 6.7–9.0 months). Overall patient survival increased over time (pre-1989 to 2015) but this was not apparent within specific treatment groups.

Conclusions. These survival estimates provide a baseline for determining the incremental benefits of recently introduced systemic treatments using targeted therapy or immunotherapy for melanoma brain metastases.

Key words: radiation therapy; stereotactic radiosurgery; melanoma; brain metastases

Introduction

Brain metastases are common in patients with advanced-stage melanoma, with a 20%–30% incidence in the first year after diagnosis of Stage IV disease, a 30%–40% incidence by 3-years, and an incidence of up to 73% in autopsy series.1-3 For patients with untreated, symptomatic brain metastases, the reported average survival times range from several weeks to a few months.4,5 Patients who have melanoma brain metastases have a worse prognosis than patients who have brain metastases from other solid tumours.6

The two main radiation therapy (RT) techniques used to treat melanoma brain metastases are whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS). WBRT has largely fallen out of favour in recent times due to its apparently limited benefits while SRS has gained favour, especially as modern imaging has enabled earlier identification of smaller lesions before they become symptomatic.
Other treatment options for melanoma brain metastases include surgery and systemic therapy. Newer systemic therapies with immune checkpoint inhibitors and BRAF-targeted agents have shown considerable benefit in patients with metastatic melanoma and evidence is accumulating that they can effectively treat brain metastases. Combinations of surgery, RT and systemic therapy are now often used, sometimes sequentially, sometimes concurrently. Many contemporary clinical management guidelines suggest multidisciplinary advice tailored for individual patients, given the complexity of treatment options and sequencing. Surgery can provide rapid symptomatic relief and may be the treatment of choice for single or few lesions or larger symptomatic metastases in surgically-accessible sites. SRS can be an alternative to surgical resection as a local therapy in patients with smaller metastases, multiple lesions or surgically-inaccessible ones. Although WBRT was a common treatment in the past, it is used much less frequently today and is often reserved for patients whose brain metastases progress during systemic therapy and who are not suitable for further surgery or SRS.

The evidence base for assessing the efficacy of RT to treat melanoma brain metastases has been weak because few well-designed randomised controlled trials have been conducted. Clinical practice guidelines have therefore been based largely on low-level evidence or consensus opinion and, as a result, recommendations vary considerably. Guidelines in the USA suggest that some patients should receive systemic therapy as their sole initial treatment modality with no need for brain-directed local therapy unless there is intracranial progression, and advise that many patients will require a combined modality approach. European guidelines recommend combination immunotherapy or targeted therapy as the preferred initial option and their consensus-based recommendations are to treat melanoma brain metastases with SRS, but with surgery when SRS is not possible, restricting WBRT to patients without systemic therapy or local therapy options. Australian guidelines provide a practice point that concurs with European opinion about the use of systemic drug therapy and suggest that this be considered as first-line treatment in asymptomatic patients; the evidence-based recommendation, however, is for SRS to be considered in patients with single or few brain metastases, while WBRT may be used for palliation. Another practice point states that surgical resection of brain metastases is recommended for metastases >1 cm in diameter in non-eloquent areas or for symptomatic metastases.

The aim of this systematic review was to analyse the results of all published studies documenting the results of RT, without systemic immunotherapy or targeted therapy, as treatment for melanoma brain metastases. The review was prompted by the need to provide a benchmark for assessing the outcomes of upfront systemic therapy for patients with melanoma brain metastases.

Materials and methods

Terms covering melanoma, brain metastases and RT (WBRT or SRS) were used in the search strategy of Medline (1947 – 24 September 2020), Embase (1947 – 25 September 2020), the Cochrane Database of systematic reviews and the Cochrane Central Trials Registry (to 30 September 2020). Full details and results are provided in Supplementary Table 1. No language restrictions were used. Included studies were those reporting outcomes in patients with melanoma brain metastases treated with RT. Studies reporting patients with a mixture of cancer types including melanoma were excluded, as were studies of melanoma in which not all patients had brain metastases. Single case reports were also excluded, as were studies in which all patients received a combination of radiation and some form of contemporary systemic therapy (immune checkpoint inhibitors, BRAF -directed targeted therapies) without a radiation-only cohort. Non-contemporary systemic immunotherapies included interferon, interleukin, BCG vaccine, and non-contemporary systemic chemotherapies included temolozolomide, fotemustine, dacarbazine, razoxane, cisplatin and lomustine.

Complete search results were imported into Endnote, duplicates were removed and references were coded for inclusion/exclusion with reasons. Those included in the review had their data extracted by one author (GW). Reference lists of identified studies and review articles were examined to identify additional studies. Extracted data included article identifiers, design features, inclusion criteria, method of diagnosis, patient characteristics, treatment details, follow-up duration, deaths, adverse events, survival data and details of recurrences or new intracranial lesions. Quality assessment was performed using a specific tool for cohort studies and the Cochrane collaboration risk of bias assessment for randomised controlled trials (RCTs).

Descriptive statistics were generated using SPSS v25 with medians and interquartile ranges (IQR),...
### TABLE 1. Studies of radiation treatment in patients with melanoma brain metastases

| Reference | Year   | Country  | Treated years | Total patients | Prospective data | Design          | Surgery | WBRT | SRS LA | SRS GK | Non-contemp |
|-----------|--------|----------|---------------|----------------|------------------|-----------------|---------|------|--------|--------|-------------|
| Carella60 | 1980   | US       | 1971–NS       | 60             | ×                | Treatment cohort |         |      |        |        |             |
| Katz61    | 1981   | US       | 1971–1980     | 63             | ×                | Treatment cohort |         |      |        |        |             |
| Vlock62   | 1982   | US       | 1970–1980     | 46             | ×                | Treatment cohort |         |      |        |        |             |
| Byrne63   | 1983   | US       | 1978–1980     | 80             | ×                | Treatment cohort |         |      |        |        |             |
| Stridsklev63 | 1984 | Norway  | 1973–1980     | 39             | ×                | Treatment cohort |         |      |        |        |             |
| Choi (A)64 | 1985  | US       | 1972–1977     | 194            | ×                | Treatment cohort |         |      |        |        |             |
| Choi (B)65 | 1985  | US       | 1972–1977     | 59             | ×                | Treatment cohort |         |      |        |        |             |
| Ziegler66  | 1986   | US       | 1972–1984     | 72             | ×                | Treatment cohort |         |      |        |        |             |
| Rate64    | 1988   | US       | 1980–1987     | 77             | ×                | Treatment cohort |         |      |        |        |             |
| Hagen67   | 1990   | US       | 1972–1987     | 35             | ×                | Treatment cohort |         |      |        |        |             |
| Stevens68  | 1992  | Australia| 1982–1990     | 129            | ×                | Treatment cohort |         |      |        |        |             |
| Somaza68   | 1993   | US       | 1988–1992     | 23             | ×                | Treatment cohort |         |      |        |        |             |
| Willner69  | 1995   | Germany  | 1985–1993     | 30             | ×                | Disease cohort   |         |      |        |        |             |
| Isokangas57 | 1996 | Finland | 1980–1994     | 60             | ×                | Treatment cohort |         |      |        |        |             |
| Skibber70  | 1996   | US       | 1979–1991     | 34             | ×                | Treatment cohort |         |      |        |        |             |
| Gieger70   | 1997   | US       | 1992–1994     | 12             | ×                | Treatment cohort |         |      |        |        |             |
| Gupta71   | 1997   | UK       | 1991–1996     | 31             | ×                | Treatment cohort |         |      |        |        |             |
| Grob72     | 1998   | France   | 1993–1996     | 35             | ×                | Treatment cohort |         |      |        |        |             |
| Sampson73  | 1998   | US       | past 20 years | 670            | ×                | Disease cohort   |         |      |        |        |             |
| Seung74    | 1998   | US       | 1991–1995     | 55             | ×                | Treatment cohort |         |      |        |        |             |
| Lavine75   | 1999   | US       | 1994–1997     | 45             | ×                | Treatment cohort |         |      |        |        |             |
| Kontsoudouakis76 | 2000 | US       | 1970–1992     | 136            | ×                | Disease cohort   |         |      |        |        |             |
| Ellerhorst77 | 2001  | US       | 1992–1995     | 87             | ×                | Treatment cohort |         |      |        |        |             |
| Buchsbaum78  | 2002  | US       | 1994–1998     | 74             | ×                | Disease cohort   |         |      |        |        |             |
| Gonzalez-Martinez79 | 2002 | US       | 1996–NS      | 24             | ×                | Treatment cohort |         |      |        |        |             |
| Mingione80  | 2002   | US       | 1989–1999     | 45             | ×                | Treatment cohort |         |      |        |        |             |
| Noel81     | 2002   | France   | 1994–2001     | 25             | ×                | Treatment cohort |         |      |        |        |             |
| Yu82       | 2002   | US       | 1994–1999     | 122            | ×                | Treatment cohort |         |      |        |        |             |
| Zacest83   | 2002   | Australia| 1979–1999     | 147            | ×                | Treatment cohort |         |      |        |        |             |
| Harrison84  | 2003   | US       | 1990–1997     | 65             | ×                | Treatment cohort |         |      |        |        |             |
| Conill85   | 2004   | Spain    | 1997–2002     | 26             | ×                | Treatment cohort |         |      |        |        |             |
| Reference | Year | Country | Treated years | Total patients | Prospective data | Design | Surgery | WBRT | SRS | LA | GK | Non-contemp |
|-----------|------|---------|---------------|----------------|------------------|--------|---------|------|-----|----|----|-------------|
| Fife et al. | 2004 | Australia | 1985–2000 (also 1952–1984) | 686 (+451) | x | Disease cohort | ✓ | ✓ |
| Meier et al. | 2004 | Switzerland | 1966–2002 | 100 | x | Disease cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Morris et al. | 2004 | UK | 1998–2003 | 102 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Radbili et al. | 2004 | US | 1996–2001 | 51 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Selek et al. | 2004 | US | 1991–2001 | 103 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Stone et al. | 2004 | US | 1989–1999 | 83 | x | Disease cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Koc et al. | 2005 | US | 1999–2003 | 26 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Panagiotou et al. | 2005 | Greece | 1986–2001 | 64 | x | Disease cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Rhtmberg et al. | 2005 | Austria | 1982–2002 | 19 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Christopoulou et al. | 2006 | UK | 1998–2004 | 29 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Gaudy-Marquesta et al. | 2006 | France | 1997–2003 | 106 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Conti et al. | 2007 | Spain | 1997–2004 | 37 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Mathieu et al. | 2007 | US | 1987–2005 | 245 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Samlowski et al. | 2007 | US | 1999–2004 | 44 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Raizer et al. | 2008 | US | 1991–2001 | 355 | x | Disease cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Redmond et al. | 2008 | US | 1998–2007 | 59 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Carruba et al. | 2009 | US | 2002–2007 | 37 | x | Disease cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Ahmad et al. | 2010 | UK | 2001–2009 | 65 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Rades et al. | 2010 | Germany | 1989–2008 | 51 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Schild et al. | 2010 | US | 2002–2010 | 267 | x | Disease cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Davies et al. | 2011 | US | 1986–2004 | 330 | x | Disease cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Eigentler et al. | 2011 | Germany | 1986–2007 | 672 | x | Disease cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Liew et al. | 2011 | US | 1987–2008 | 333 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Skeie et al. | 2011 | Norway | 1996–2006 | 77 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Zakrzewski et al. | 2011 | US | 2002–2008 | 89 | x | Disease cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Bernard et al. | 2012 | US | 2004–2010 | 54 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Hauswald et al. | 2012 | Germany | 2000–2011 | 87 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Knisely et al. | 2012 | US | 2002–2010 | 77 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Koay et al. | 2012 | US | 2005–2011 | 296 | x | Disease cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Lo et al. | 2012 | US | 2000–2007 | 28 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Salvati et al. | 2012 | Italy | 1997–2007 | 84 | x | Treatment cohort | ✓ | ✓ | ✓ | ✓ | ✓ |
| Reference | Year | Country     | Treated years | Total patients | Prospective data | Design | Surgery | WBRT | SRS | Non-contemp |
|-----------|------|-------------|---------------|----------------|------------------|--------|---------|------|-----|-------------|
| Mathew102 | 2013 | US          | 2008-2011     | 58             | x                | Treatment cohort |        |       |     |             |
| Miller103  | 2013 | Germany     | 2000-2010     | 34             | x                | Treatment cohort |        |       |     |             |
| Partl104  | 2013 | Austria     | 1988-2009     | 87             | x                | Treatment cohort |        |       |     |             |
| Silk41     | 2013 | US          | 2005-2012     | 70             | x                | Treatment cohort |        |       |     |             |
| Zukauskaite104 | 2013 | Denmark | 1995-2009     | 80             | x                | Treatment cohort |        |       |     |             |
| Dyer105    | 2014 | US          | 2000-2010     | 147            | x                | Treatment cohort |        |       |     |             |
| Marcus106  | 2014 | US          | 1998-2010     | 135            | x                | Treatment cohort |        |       |     |             |
| Neal107    | 2014 | US          | 2000-2009     | 129            | x                | Treatment cohort |        |       |     |             |
| Rades108   | 2014 | Germany     | 2000-2013     | 54             | x                | Treatment cohort |        |       |     |             |
| Vecchio109 | 2014 | Italy       | 1994-2010     | 115            | x                | Treatment cohort |        |       |     |             |
| Christ110  | 2015 | US          | 2005-2011     | 103            | x                | Treatment cohort |        |       |     |             |
| Frakes111  | 2015 | US          | 2008-2012     | 28             | x                | Treatment cohort |        |       |     |             |
| Hauswald112 | 2015 | Germany     | 1990-2011     | 84             | x                | Treatment cohort |        |       |     |             |
| Ivanov113  | 2015 | Russia      | 2009-2013     | 95             | x                | Treatment cohort |        |       |     |             |
| Ly114      | 2015 | US          | 2009-2012     | 52             | x                | Treatment cohort |        |       |     |             |
| Osthheimer115 | 2015 | Germany     | 1992-2011     | 100            | x                | Treatment cohort |        |       |     |             |
| Gallaher116 | 2016 | US          | since 2006    | 19             | x                | Treatment cohort |        |       |     |             |
| Gupta29    | 2016 | UK          | NS            | 18             | Yes              | RCT     |         |     |     |             |
| Patel117   | 2016 | US          | 2007-2014 (abstract says 2005-2013) | 87 | x | Treatment cohort |        |       |     |     |             |
| Rades118   | 2016 | Germany     | 2000-2015     | 23             | x                | Treatment cohort |        |       |     |             |
| Szyszka-Chare39 | 2016 | Poland     | 1985-2012     | 110            | x                | Disease cohort |        |       |     |             |
| Wolf119    | 2016 | US          | 2012-2015     | 80             | x                | Treatment cohort |        |       |     |             |
| Acharya120 | 2017 | US          | 2006-2016     | 72             | x                | Treatment cohort |        |       |     |             |
| Ali121     | 2017 | US          | 2008-2016     | 58             | x                | Treatment cohort |        |       |     |             |
| Feng122    | 2017 | US          | 2007-2014     | 87             | x                | Treatment cohort |        |       |     |             |
| Kaidar-Person123 | 2017 | US       | 2007-2015     | 58             | x                | Treatment cohort |        |       |     |             |
| Minniti124 | 2017 | Italy       | 2008-2015     | 120            | x                | Treatment cohort |        |       |     |             |
| Patel125   | 2017 | US          | 2009-2013     | 54             | x                | Treatment cohort |        |       |     |             |
| Pessina126 | 2017 | Italy       | 2011-2015     | 53             | x                | Treatment cohort |        |       |     |             |
| Sperduto57 | 2017 | US          | 2006-2013     | 823/481        | x                | Disease cohort |        |       |     |             |
| Xu128      | 2017 | US          | 2010-2014     | 65             | x                | Treatment cohort |        |       |     |             |
| Diao(A)129 | 2018 | US          | 2006-2015     | 72             | x                | Treatment cohort |        |       |     |             |
as data were not normally distributed. Medians were tested for difference using the non-parametric median test, Fisher’s exact (2-sided). When three or more studies reported the same outcome for the same treatment group, data were pooled and analysed.

## Results

### Search results

Search results and exclusions are shown in Figure 1. There were 142 publications between 1980–2020, 112 of which were unique studies or were the primary publication of a series of publications, and 30 were duplicates or non-primary publications (Table 1.) Seven studies were published only as abstracts. 57.1% (64/112) of the publications were from the USA, 30.4% from Europe, and 11.6% from other countries. Sample sizes ranged from 7–1304 patients (median 77). While our focus was on RT, most articles (96/112) included patients who had received a variety of other therapies for their brain metastases. Surgery was reported in 79 studies, WBRT in 95 studies, SRS in 84 studies and 64 reports included subsets of patients who received some form of systemic therapy as well as RT. Outcomes for the subsets of patients treated with both RT and any form of contemporary systemic therapy were not analysed. Amongst studies reporting the use of SRS, five reported using both linear accelerator and Gamma Knife methods, 32 used Gamma Knife only, 18 used linear accelerator only and 29 did not report which was used.

| Reference   | Year | Country | Treated years | Total patients | Prospective data | Design                                                                 | Surgery | WBRT | SRS | Non-contemp |
|-------------|------|---------|---------------|----------------|------------------|-------------------------------------------------------------------------|---------|------|-----|-------------|
| Diao(8)     | 2018 | US      | 2006–2015     | 91             | x                | Treatment cohort                                                       |         |      | ✔  | ✔           |
| Fang(23)    | 2018 | US      | 2003–2011     | 235            | x                | Disease cohort                                                         | ✔       | ✔    | ✔  | ✔           |
| Gabani(24)  | 2018 | US      | 2011–2013     | 1104           | x                | Treatment cohort                                                       | ✔       | ✔    | ✔  | ✔           |
| Kano(25)    | 2018 | US      | 1988–2012     | 422            | x                | Treatment cohort                                                       | ✔       | ✔    | ✔  | ✔           |
| Kotecha(26) | 2018 | US      | 1987–2014     | 366            | x                | Disease cohort                                                         | ✔       | ✔    | ✔  | ✔           |
| Ladwa(27)   | 2018 | Australia | 2009–2016    | 142            | x                | Disease cohort                                                         | ✔       | ✔    | ✔  | ✔           |
| Matsunaga(28) | 2018 | Japan   | 1991–2015     | 177            | x                | Treatment cohort                                                       | ✔       | ✔    | ✔  | ✔           |
| Tio(29)     | 2018 | Australia | 2011–2014    | 355            | x                | Disease cohort                                                         | ✔       | ✔    | ✔  | ✔           |
| Zubatkin(30) | 2018 | Russia  | 2009–2014     | 78             | x                | Treatment cohort                                                       | ✔       | ✔    | ✔  | ✔           |
| Hauswald(31) | 2019 | Germany | 2013–2017     | 7              | Yes              | RCT                                                                     |         |      | ✔  | ✔           |
| Hong(32)    | 2019 | Australia | 2009–2017    | 215            | Yes              | RCT                                                                     | ✔       | ✔    | ✔  | ✔           |
| Jardim(33)  | 2019 | Australia | 2015–2017    | 43             | x                | Treatment cohort                                                       | ✔       | ✔    | ✔  | ✔           |
| Mastorakos(34) | 2019 | US      | 2011–2015     | 198            | x                | Treatment cohort                                                       | ✔       | ✔    | ✔  | ✔           |
| Phillips(35) | 2019 | Canada  | 2000–2018     | 277            | NS               | Disease cohort                                                         | ✔       | ✔    | ✔  | ✔           |
| Tjong(36)   | 2019 | Canada  | 2008–2017     | 97             | x                | Treatment cohort                                                       | ✔       | ✔    | ✔  | ✔           |
| McHugh(37)  | 2020 | New Zealand | 2005–2017    | 110            | x                | Treatment cohort                                                       | ✔       | ✔    | ✔  | ✔           |
| Pomeranz-Krumme(38) | 2020 | US      | 2010–2018     | 25             | x                | Treatment cohort                                                       | ✔       | ✔    | ✔  | ✔           |

GK = Gamma Knife methods; Non-contemp = non-contemporary systemic therapy; LA = linear accelerator; SRS = stereotactic radiosurgery; WBRT = whole brain radiation therapy stereotactic radiosurgery
Risk of bias assessment

Details of the risk of bias assessment for each study are provided in Supplementary Table 2 and summarised in Figure 2. Of the three RCTs, none reported how their randomisation sequence was generated but all reported complete outcome data and clinically-relevant outcomes. Two of the three trials28,29 were closed early due to poor accrual and had sample sizes of 7 and 18, greatly limiting the reliability of their results. Baseline characteristics for the different treatment arms were reported and similar for the trial of 18 patients28 but were not reported for the trial of 7 patients.28 The largest trial10 had 215 patients, and while not stratifying for previous treatments, randomisation was effective as previous treatments were well balanced between the two study arms, as were baseline characteristics. This trial provided the most reliable data for identifying the effects of adjuvant WBRT in conjunction with surgery and/or SRS for patients with 1–3 brain metastases.

For the 109 cohort studies, selection bias was a significant concern, as 77 studies (71%) did not provide information specifying how a treatment choice was made. Sixteen studies reported that there were no significant differences in patient characteristics such as age, number of brain metastases and tumour volume between treatment groups, while 11 studies reported significant differences between patients treated using different modalities. The remaining 82 studies did not report similarities or differences in patient characteristics, although in 21 studies the patient characteristics were provided. Fifty-six studies did not report if or how the diagnosis of melanoma brain metastases was verified; this may have resulted in misclassification of disease, although this is probably a relatively inconsequential source of bias.

Many studies reported analyses of one treatment without considering prior and subsequent forms of treatment (e.g. SRS preceded by surgical resection). Our analysis was based on grouping data based on all treatments received for brain metastases.

Treatment decisions

Five studies (651 patients) included only asymptomatic patients, nine studies (532 patients) included only symptomatic patients, 30 studies (5906 patients) had a mixture of asymptomatic and symptomatic patients and 57 studies (5452 patients) did not report this detail.

Seven of the 95 studies provided specific criteria for choosing WBRT in their patients; four stated that it was used for multiple brain metastases31-34, three reported its use for progression of brain metastases31,35,36, one its use for single, large metastases36 and one its use for symptomatic metastases.37

Nineteen studies reported criteria for choosing SRS. Twelve stated that it was used for small metastases, often <30mm in diameter, nine required good performance status as measured by Karnofsky performance score (KPS), with four of these using a cut-off of KPS ≥ 70. Seven studies used SRS for a small number of brain metastases (usually 1–3). Five studies used SRS when metastases were inaccessible for surgery, four used it for multiple metastases, but only one specified a number (<9), and three stated that it was used for asymptomatic lesions. Other infrequently used criteria were; expected survival > 3 months, non-life threatening lesions, high risk for surgery, including proximity to the brain stem or optic nerve. A single study52 reported criteria for using a combination of SRS and WBRT, stating that this was used for ≥ 5 lesions.

Fourteen studies provided criteria for surgery; a single metastasis (5 studies), few or <3 metastases
(2 studies), accessible metastases (8 studies), symptomatic metastases (4 studies), stable extracranial disease (4 studies), good KPS (1 study), life expectancy > 3 months (1 study), and 2–3 brain metastases if one was life-threatening (2 studies).

Treatment groupings

Many treatment groupings that included RT were reported but outcomes were not reported for all groups. Given the limited amount of data for clearly-defined treatment groups, we re-grouped data into two additional treatment options; (i) patients treated with WBRT and any of SRS, surgery or non-contemporary systemic therapy, and (ii) patients treated with SRS and any of WBRT, surgery, or non-contemporary systemic therapy.

Patient characteristics within treatment groups

Patient characteristics within different treatment groups are summarised in Table 2. For all treatment types, there was a predominance of males. Patients treated with WBRT alone were somewhat younger than those receiving SRS and patients undergoing WBRT were less likely to have a single brain metastasis. While the data were sparse, there was considerable overlap in patient characteristics across different treatment modalities, indicating that the choice of treatment was not consistently determined by age, presence of symptoms, number of metastases or control of primary disease.

Median survival

Ninety-six studies reported median survival for all patients or subsets of patients and there were 49 different treatment groupings.

Within-study comparisons were possible for six treatment groupings (Table 3.). Eleven studies reported median survival for patients treated with WBRT alone or with WBRT and surgery. The median survival in the WBRT alone group was 4.0 months (IQR 3.0–4.0 months), significantly less than for those treated with surgery and WBRT (11.0 months, IQR 8.8–11.8 months) (p = 0.002). Expressing these findings as a median difference between treatments, patients who had WBRT and surgery had a 5.4 month (IQR 4.6–8.0 months) longer survival compared with those treated with WBRT alone. In this group of 11 studies, three reported using surgery in patients with a single brain metastasis and two studies reported features for treatment with WBRT, this being good performance status alone in one study and multiple lesions, good performance and symptoms in the second study. Significant differences in median survival were also apparent between WBRT alone and surgery alone (6.0 months longer for surgery) and median survival for patients treated with WBRT plus SRS was 3.4 months longer than with WBRT alone. In the five studies with groups treated with WBRT alone or surgery alone, three reported that surgery was used for a single or few brain metastases and WBRT was used for patients with more than one brain metastasis (1 study) and for patients with good performance status (1 study). None of the four studies reporting patients treated with WBRT alone or WBRT+SRS described features leading to these treatment choices. There were no significant differences in median survival between WBRT alone and SRS alone, or between WBRT alone and WBRT with chemotherapy, or SRS alone compared to WBRT with SRS.

Summarised findings for median survival in all studies are detailed in Table 3 and for other groupings in Supplementary Table 4. The group treated with WBRT alone had the shortest survival; 3.5 months (IQR 2.4–4.0 months). For the group treated with surgery and WBRT, the median survival was 11.0 months (IQR 7.8–12.0 months). Adding chemotherapy to WBRT appeared to provide lit-
Thompson JF et al. / Radiation therapy for melanoma brain metastases 275

No studies reported median survival within treatment groups separately for asymptomatic and symptomatic patients. For the 5 studies that included only asymptomatic patients, there were no common treatment groups. In 4 studies of 89 symptomatic patients, the median survival for the treatment group WBRT with surgery was 9.2 months (IQR 5.4–12.8 months) and for WBRT with any other treatment; 5 months (IQR 2.5–10.0 months, 7 studies of 245 patients).

Median survival in different time periods

Median survival over time was explored by grouping the data into three time periods based on the first year of patient recruitment within each study (Table 4). Eighty-one studies reported median survival for their whole cohort irrespective of treatment, and these showed increasing survival over the years. There were significant differences in median survival between the pre-1989 group compared with the 1990–2002 (p = 0.017) and 2003–2015 groups (p = 0.002) and also between the groups first treated in 1990–2002 compared with 2003–2015 (p = 0.021).

Median survival within treatment groups over the three time periods showed a trend toward slightly increased survival in more recent years, but none of the differences was statistically significant.

One-year survival

Fifty-six studies reported 1-year survival for all patients or subsets of patients (Table 3). Pooled
### TABLE 3. Pooled outcome results for studies of radiation treatments

| Treatment Description | Groups | Median survival (Patients) | 1-year survival rate, % (IQR) | 1-year local control rate (Patients) | 6-mo new brain lesion rate (Patients) | Serious adverse events |
|-----------------------|--------|-----------------------------|-------------------------------|-------------------------------------|--------------------------------------|-----------------------|
| **WBRT vs. WBRT + Surgery** | WBRT | 11 (980) | 4.0 (3.0, 4.0) | 0 | 0 | 0 | Not reported |
| | WBRT+Surg | 11 (439) | 11.0 (8.8, 11.8) | 0 | 0 | 0 | |
| | All studies | 26 (2185) | 3.5 (2.4, 4.0) | 7 (189) | 9.0 (0.0, 22.5) | 174 | 5.0 (0.0, 12.0) | Post-op death; Hemorrhage; 3/72 lesions (1 study) |
| | WBRT | 16 (619) | 11.0 (7.8, 12.0) | 1 (19) | 41.0 | 0 | |
| | WBRT+Surg | 11 (439) | 11.0 (8.8, 11.8) | 0 | 0 | 0 | |
| **WBRT vs. SRS** | WBRT | 5 (699) | 3.9 (3.6, 5.0) | 0 | 0 | 0 | Gr3 tox; 3/39 (1 study) |
| | SRS | 5 (234) | 9.8 (7.6, 16.5) | 0 | 0 | 0 | Post-op death; 2% (1 study) |
| | All studies | 9 (359) | 8.7 (6.2, 10.4) | 1 (16) | 43.0 | 0 | 2% (1 study) |
| **WBRT + Chemotherapy vs. SRS** | WBRT | 3 (931) | 4.1 (3.2, 5.6) | 0 | 0 | 0 | |
| | SRS | 3 (980) | 8.8 (7.2, 11.4) | 0 | 0 | 0 | |
| | All studies | 8 (1188) | 7.5 (6.7, 9.0) | 6 (330) | 35.5 (20.8, 47.8) | 4 (260) | 7.0 (6.2, 8.5) | Hemorrhage; 4/56 lesions (1 study) |
| | SRS-GK | 5 (208) | 7.0 (5.6, 7.8) | 1 (83) | - | 0 | 0 |
| **SRS vs. WBRT+SRS** | SRS | 5 (881) | 7.0 (6.0, 8.1) | 1 (83) | 26.0 | 0 | 0 |
| | WBRT+SRS | 3 (544) | 6.5 (5.7, 6.5) | 1 (39) | 23.0 | 0 | 0 |
| | All studies | 12 (516) | 7.0 (6.0, 8.0) | 3 (58) | 36.0 (29.5, 37.0) | 0 | 0 |
| | SRS type | SRS-LA | 0 | 0 | 0 | 0 | |
| | SRS-NS | 3 (980) | 8.8 (7.2, 11.4) | 0 | 0 | 0 | |
| **SRS+ Chemotherapy vs. SRS** | WBR+Chemo | 4 (148) | 2.5 (1.0, 4.2) | 0 | 0 | 0 | Gr3 tox; 3/39 (1 study) |
| | WBRT+Chemo | 4 (62) | 5.5 (4.0, 6.0) | 1 (7) | 10.0 | 0 | 0 |
| | All studies | 6 (137) | 4.3 (2.8, 6.0) | 2 (15) | 10.0 (8.7, 13.7) | 0 | 0 |
| | SRS vs. WBRT+SRS** | SRS | 5 (881) | 7.0 (6.0, 8.1) | 1 (83) | 26.0 | 0 | 0 |
| | WBRT+SRS | 3 (544) | 6.5 (5.7, 6.5) | 1 (39) | 23.0 | 0 | 0 |
| | All studies | 12 (516) | 7.0 (6.0, 8.0) | 3 (58) | 36.0 (29.5, 37.0) | 0 | 0 |
| **SRS + Surgery** | SRS+Surg | 4 (197) | 7.4 (6.5, 10.7) | 1 (8) | 38.0 | 0 | 0 |
| | All studies | 4 (200) | 13 (9.4, 13.5) | 1 (60) | 58.0 | 1 (34) | 52.0 | 1 (34) | 52.0 | Hemorrhage: 1/106 pt (1 study), 4/56 lesions (1 study), Radiation necrosis: 1/106 pts (1 study) |
| **WBRT+ other treatments** | All studies | 47 (2230) | 7.2 (4.6, 9.4) | 19 (827) | 21.4 (13.6, 37.0) | 5 (208) | 1.0 (0.0, 16.0) | WBR specific; Death: 6/194 (1 study), headache; 12/26 (1 study), Toxicity > Gr3; 3/7 (1 study), LeukopeniaGr1-2; 2/9 (1 study) Hemorrhage: 1/20 (1 study) |
| **SRS+ other treatments** | All studies | 42 (2702) | 8.0 (6.2, 10.9) | 35 (2644) | 31.0 (25.0, 39.0) | 16 (1043) | 40.0 (82.0) | 10 (1261) | 49.0 (42.0, 56.0) | SRS specific: Hemorrhage: 1/48 (4 studies, 441 patients), Radiation necrosis: 6.6% (4 studies, 241 patients), Seizure-edema-death: 1/55 (1 study), Complications: 4/104 (1 study) |

Chemo = chemotherapy; GK = Gamma Knife methods; Gr = grade; i = individual study data; IQR = interquartile range; LA = linear accelerator; non-contemp = non contemporary systemic therapy; SRS = stereotactic radiosurgery; Surg = surgery; WBRT = whole brain radiation therapy.
data from 7 studies of 189 patients treated with WBRT alone gave a 1-year survival rate of 9.0% (IQR 0.0–22.5%) while for SRS alone the 1-year survival was 35.5% (IQR 20.8–47.8%, p = 0.041) in six studies of 330 patients. In the compiled grouping of WBRT with or without any other therapy, the 1-year survival was 21.4% (IQR 13.6%–37.0%). For the SRS grouping with or without any other therapy (WBRT, surgery, non-contemporary systemic therapy), the 1-year survival was 31.0% (IQR 25.0–39.0%) across 35 studies of 2644 patients. In the only completed RCT30, 1-year survival in the group treated with adjuvant WBRT was 58.4% (95%CI 49.6%–68.9%) compared with 54% (95%CI 45.3%–64.3%, p = 0.89) for those treated without WBRT.

Local control

Most studies defined local control as a reduction in metastasis size or stability of metastasis size, as determined by follow-up imaging. Fifty-three studies reported local control data, 21 without a defined time frame and for almost all it was reported for the total patient group, not separately for different treatment groupings. The 1-year local control rate was highest for those treated with SRS; 76% (IQR 62.8%–88.5%). The 1-year local control rate after WBRT was 5.5% (IQR 0.0%–12.0%, 1 study, 74 patients). For the 550 patients in 11 studies that treated patients with any combination of WBRT, SRS, surgery and non-contemporary systemic therapy, the 1-year local control rate was 68.0% (IQR 66.072.0%). There was no difference in the 1-year local control rate between Gamma Knife SRS and linear accelerator-based SRS (69% vs. 72.0%).

New brain lesions

Thirty-six studies reported rates of new brain lesions developing during the follow-up period. For the 23 studies that reported new brain lesions at 6-months the median rate was 44% (IQR 32.0%–53.0%) and at 12-months 67% (IQR 62.3%–71.5%, 14 studies). Three studies (189 patients) reported a 6-month new brain lesion rate in patients treated with WBRT and other treatment, giving a median rate of 39% (IQR 34.0%–44.5%) and for SRS and other treatment a rate of 47% (IQR 34.5%–55.5%, 11 studies, 1306 patients). At 12 months, the RCT of patients with 1–3 brain metastases reported a new brain lesion rate of 42% in the adjuvant WBRT group and 50.5% in those who did not receive adjuvant WBRT (p = 0.22). For patients treated with SRS, the proportion who developed a new brain lesion by 12 months was 67% (IQR 57.0%–75.0%; 11 studies, 1278 patients).

Neurologic deaths

Neurologic death was reported in 40 studies but only 11 reported this for a defined treatment group. The definition of neurologic death was variable. Only one study provided a definition that combined an objective measurement with radiological and clinical neurologic changes.41 Other studies used brain lesion progression and/or recurrence (18 studies), brain hemorrhage alone (4 studies), neurologic dysfunction alone (4 studies) or other features (3 studies) as criteria for designating a death as neurologic. The reported proportion of patients with a neurologic cause of death ranged from 0% to 90%. Three studies reported the propor-
tion of patients treated with WBRT with or without surgery who experienced neurologic death (0%, 24%, 83%). Two studies reported neurologic deaths for patients treated with WBRT alone (14%, 88%), two studies reported neurologic deaths in those treated with SRS and WBRT (50%, 58%) and two studies reported neurologic death in patients treated with WBRT with or without systemic therapy (57%, 75%). Re-grouping the data into SRS with any other treatment (6 studies), gave a median neurologic death rate of 53% (IQR 44.8%–69.4%), while for WBRT and any other treatment (10 studies), the median was 50% (IQR 19.3%–62.3%).

**Effect of number of brain metastases on survival**

Seventy-six studies assessed whether the number of brain metastases present at diagnosis impacted survival, with 58 reporting significantly improved survival for patients with single lesions while 18 reported no impact. In the RCT\(^3\), the number of brain metastases (1 \(v\) 2–3) did not influence overall survival. Only three studies reported these data within specific treatment groups.\(^4\,4^2\,4_3\) Two studies\(^4\,4_3\) reported survival in patients treated with WBRT alone comparing those with one metastasis to those with \(\geq 2\) brain metastases; one study\(^4_4\) reported better survival in the single metastasis group (16 weeks) compared to the multiple metastases group (12 weeks) while the other study\(^4_3\) did not (9 weeks for a single metastases and 11 weeks for multiple metastases).

**Adverse effects of radiation therapy**

Adverse effects of RT were reported in 41 studies, but only 17 reported events within treatment groups and these were primarily studies that included systemic therapy. Radiation necrosis (with various radiological and/or pathological definitions) was reported in 13 studies, 11 of which focussed on SRS. The median rate was 8.1% (IQR 3.4%–22.2%). In the four studies using Gamma Knife SRS, the median radiation necrosis rate was 3.4% (IQR 0.47%–5.49%) and for the 4 studies using linear accelerator SRS it was 22.2% (IQR 15.59%–25.66%). Two studies reported this for WBRT, with rates of 1.9% and 3.6%. Eight studies reported intracranial haemorrhage in their patients, with seven studies focussed on SRS, giving a median rate of 14.7% (IQR 0.94–18.8%). Three studies using Gamma Knife SRS reported brain haemorrhage rates with a median rate of 18.8% (IQR 9.86–24.01%) and two studies used linear accelerator SRS, with brain haemorrhage rates of 15% and 16%. Other reported adverse effects included headaches, seizures, skin reactions, fatigue, nausea, alopecia and confusion but because data were sparse and pooled analysis was not possible.

**Discussion**

For unbiased comparisons of an intervention, prospective randomised controlled trials are required. Although RT has long been used in the management of patients with melanoma brain metastases, there have been only three randomised trials of RT for this condition, and only one of these\(^3\) recruited sufficient patients for meaningful analysis. However, a large number of non-randomised studies (n = 109) have published outcomes for patients with melanoma brain metastases treated with various RT regimens. The number of patients in each study varied, but most (86%) had fewer than 200 patients and medians of 20–30 for different treatment groups. This low number of patients per treatment group reduces the precision of estimates of survival duration within each study but when pooled over many studies, greater precision can be achieved. These non-randomised studies were of variable quality with multiple study design features poorly reported, hindering our understanding of how patients were selected for the studies and how representative they were. Over the 40-year period encompassed by this review there was a consistent trend towards improvement in the median survival of patients with melanoma brain metastases. This is likely due to earlier diagnosis of small brain metastases using newer imaging technologies, as well as a general improvement in treatment. However, we were unable to demonstrate an improvement in median survival within treatment groups over time, possibly due to a paucity of data for individual treatment groups.

Within-study comparisons were possible for only six treatment groupings. These analyses demonstrated significantly longer median survival times for patients who were treated with surgery alone (+6 months), WBRT and surgery (+7 months) and WBRT and SRS (+4 months) compared to those treated with WBRT alone (4 months). The better survival after surgery or SRS than after WBRT is almost certainly due mainly to selection issues since patients with fewer lesions, better performance status and a lower burden of extracranial disease were more likely to receive surgery or SRS and these fea-
turers are associated with improved survival. The benefit of within-study comparisons is the presence of a “control” group in the same study, meaning that treatment decisions, management and outcome assessment were likely to be more consistent than comparisons with studies performed at different institutions and at different times.

Many treatment groups were not represented in the within-study comparisons and were therefore reviewed across studies to provide estimates of median and 1-year survival rates for major treatment groupings. Patients treated with WBRT alone had a median survival of only 3.5 months, while those treated with SRS had a median survival of 7.5 months. Data were somewhat limited but suggest that linear accelerator-based SRS resulted in similar local control rates as Gamma Knife-based SRS. This is a reassuring finding as there is no randomised comparison of different SRS techniques for brain metastases. The combination of surgical removal of the lesion/s and WBRT was associated with substantially improved median survival, apparently adding 7.5 months of life, with median survival 11.0 months. These across-study median survival estimates are reassuringly consistent with the within-study findings. These findings, however, conflict with those of the randomised controlled trial that showed no survival gain and no improvement in intracranial control or perfor- rance status with adjuvant WBRT after adequate local treatment of 1–3 brain metastases. This may be because about one third of the patients in the RCT also received SRS, which may have enhanced survival and limits our ability to compare their outcomes with those of patients treated with WBRT and surgery but no SRS.

Median survival for patients treated with surgery and SRS also showed benefit (+5.5 months), with a median survival of 13 months. Again, this is likely attributable to selection of patients with fewer metastases for surgery and SRS. Importantly, the data confirmed a lack of any survival benefit from the addition of non-contemporary systemic chemotherapy or non-contemporary forms of immunotherapy.

Limitations

Risk of bias assessment for these studies showed that many of the non-randomised studies included patients who were treated without explanation of how treatment choices were made. In the 30% of studies that did report treatment selection criteria there was considerable variation, reflecting the diversity of clinical practice between and even within individual centres and over the 40-year study period. This selection bias limited our ability to apply results to specific patient groups as we could not be sure in many instances which types of patients received particular treatments. Also, important prognostic factors such as performance status and extent of extracranial disease were rarely reported within treatment groups. Compiling the rather limited patient characteristics data for the different treatment groups showed that there was considerable overlap in the types of patients receiving WBRT and SRS. There was a degree of consistency in offering surgery to patients with a single or few brain metastases, as almost half of the studies that reported criteria for surgery stated this. However, it was not possible to determine survival outcomes for patients who underwent surgery for a single brain metastasis followed by RT as this was not reported. Most studies that analysed the effect on survival of having a single versus multiple brain metastases, irrespective of other treatments, reported improved survival with a single metastasis. This suggests that patients who undergo surgery have a greater likelihood of increased survival at baseline. A valid comparison of different RT modalities should consider or control for factors that have a major impact on survival, an issue not possible to evaluate using the current evidence.

Further difficulties arose in relation to the multitude of different outcomes reported that could not be easily combined. For example, median, 6-month, 1 and 2-year survival rates were often reported but recurrence/regrowth at a treated site versus new lesions at new sites were often not clearly specified within treatment groups or time frames. Similarly, the definitions of neurologic death varied between studies. Only one study provided a robust, measurable definition of this while others relied on less precise features. Definitions of radiation necrosis were also variable, provided in only eight studies, each of which was different; three relied solely on various imaging features, one solely on clinical signs of bleeding and four on combined imaging features and clinical signs. Radiation necrosis and neurologic death are important endpoints being measured in current clinical trials and an assurance of similar definitions and measurements will greatly aid interpretation of these outcomes across studies. A possible solution to the diverse and variably-defined outcomes in studies would be for clinicians, researchers and patients to agree on a minimum required and consistently-defined outcome reporting set, as has been done for other diseases.
such as rheumatoid arthritis, ulcerative colitis, and lung cancer.\textsuperscript{45-47} Researchers have developed a process for selecting outcomes of interest to clinicians and patients, and deciding how these can be implemented in their respective settings.\textsuperscript{48,49} A similar strategy for future studies of patients with melanoma brain metastases would be feasible.

Few studies reported whether the treatments resulted in relief of symptoms for symptomatic patients. Australian guidelines suggest that WBRT may be considered in a palliative setting for relief of symptoms, and there are many anecdotal reports of its value in this situation, but we found little reported evidence to support the effectiveness of this option.

Use of treatment groupings was a substantial limitation to interpretation, as many studies grouped together patients who received different treatment combinations. Ideally more uniform treatment groups should be used but this would require studies of much greater size to achieve adequate numbers within each group.

Conclusions

One randomised trial and many observational studies have reported survival outcomes for patients treated with RT for melanoma brain metastases. WBRT alone and SRS alone resulted in median survival times of about 4 and 8 months respectively. For patients who were selected to have surgery in addition to RT, there was a 5–7-month improvement in survival, however, this likely reflects the tendency to select patients with a better baseline prognosis relative to patients not offered surgery. While most studies included in this review were not optimal for determining the efficacy of an intervention, they provide the only evidence currently available. Given the improved efficacy of newer systemic therapies in the treatment of metastatic melanoma, RT alone today has a diminished role in the management of melanoma brain metastases, and large-scale trials or cohort studies of RT alone would be considered unethical. Therefore, this systematic review of the various forms of RT with or without surgery provides baseline estimates for measuring the incremental benefits of contemporary systemic therapies over RT with or without surgery in the treatment of patients with melanoma brain metastases.

Acknowledgments

Financial support was provided by an Australian National Health and Medical Research Council Program Grant (APP1093017) to JFT and by Melanoma Institute Australia.

References

1. de la Monte SD, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983; 43: 3427-33. PMID: 6850649
2. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival. Cancer 1978; 42: 660-8. doi: 10.1002/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO;2-E
3. Zhang D, Wang Z, Shang D, Yu J, Yuan S. Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study. Melanoma Res 2019; 29: 77-84. doi: 10.1097/CRR.0000000000000538
4. Chukwuere U, Batchelor T, Brastianos P. Management of brain metastases in patients with melanoma. J Oncol Practice 2016; 12: S36-42. doi: 10.1200/JOP.2016.011882
5. Raizer JJ, Wu WJ, Panagexas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008; 10: 199-207. doi: 10.1215/15228517-2007-058
6. Winston K, Walsh J, Fischer E. Results of operative treatment of intracranial metastatic tumors. Cancer 1980; 45: 2639-45. doi: 10.1002/1097-0142(19800515)45:10<2639::AID-CNCR2820451025>3.0.CO;2-O
7. Pasquali S, Hadjinselouau AV, Chiarion Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2018; 2: CD012113. doi: 10.1002/14651858.CD012113.pub2
8. Hao C, Tian J, Liu H, Li F, Niu H, Zhu B. Efficacy and safety of anti-POD-1 and anti-POD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. Medicine 2017; 96: e7325. doi: 10.1097/MD.0000000000007325
9. Dequep P, Lorigan P, Jansen JP, van Baardwijk M, Ouwens MJ, Kopatapi S. Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist 2012; 17: 1376-85. doi: 10.1634/theoncologist.2011-0427
10. Rulli E, Legramandi L, Salvati L, Mandala M. The impact of targeted therapies and immunotherapy in melanoma brain metastases: a systematic review and meta-analysis. Cancer 2019; 125: 3776-89. doi: 10.1002/jcc.32375
11. van Opijn MP, Dirven L, Coremans IEM, Tapshoorn MJ, Kapiteijn EHW. The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: a systematic review. Int J Cancer 2020; 146: 1479-89. doi: 10.1002/ijc.32696
12. Coit DG, Thompson JA, Albertini MR, Barker C, Carson III WE, Contreras C, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. National Comprehensive Cancer Network 2019; 17: e1. doi: 10.6004/jnccn.2019.0018
13. Long GS, Shivalingam B, Carlozzi M, Hong, A, Atkinson, V, Kefford, R, et al. Summary of recommendations and practice points: treatment approaches to brain metastases for patients with melanoma. Sydney: Cancer Council Australia; 2019 [updated 2019 Mar 7]; [cited 2021 Jan 28]. Available at: https://wiki.cancer.org.au/australia/Guidelines/Melanoma/Summary_of_treatment_approaches_to_brain_metastases
14. Micheliin O, Van Akkooi A, Acierto P, Dummer R, Kelholz U. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1884-901. doi: 10.1093/annonc/mdz411
88. Redmond AJ, Diluna ML, Hebert R, Moltiera JA, Desali R, Knisley JP, et al. Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival. J Neurosurg 2008; 109 (Suppl): 99-105. doi: 10.1016/j.jns.2008.10.016

89. Carrubba CJ, Vitzan TW. Factors affecting the outcome after treatment for metastatic melanoma to the brain. Surg Neurol 2009; 72: 707-11. doi: 10.1016/j.surneu.2009.03.005

90. Ahmad S, Ricco A, Brown R, Hanlon A, Yang J, Feng J, et al. Single institutional experience of stereotactic radiosurgery alone for first brain metastatic event and salvage of second brain metastatic event in a community setting with review of the literature. Front Radiat Ther Oncol 2017; 3: 1-8. doi: 10.3389/fonc.2017.00032

91. Rades D, Heisterkamp C, Huttonlocher S, Bohlen G, Dursl J, Haatanen T, et al. Dose escalation of whole-brain radiotherapy for brain metastases from melanoma. Int J Radiat Oncol Biol Phys 2010; 77: 537-41. doi: 10.1016/j.ijrobp.2009.05.001

92. Schild SE, Behl D, Markovic SN, Brown PD, Sander JR, Deming RL, et al. Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiotherapy? Am J Clin Oncol 2010; 33: 633-6. doi: 10.1097/COC.0b013e3181e45b4

93. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Outcome predictors of Gamma knife surgery for melanoma brain metastases. Cancer 2010; 117: 1697-703. doi: 10.1002/cncr.25631

94. Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjana A, Flickinger JC, et al. Outcome predictors of gamma knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 2011; 114: 769-79. doi: 10.3171/2010.5.JNS10104

95. Skeie BS, Skeie GO, Enger PO, Ganz JC, Hegdal JL, Ystevik B, et al. Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged survival. World Neurosurg 2011; 75: 684-91; discussion 598-603. doi: 10.1016/j.wneu.2010.12.054

96. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastasis survival. Cancer 2011; 117: 1711-20. doi: 10.1002/cncr.25643

97. Bernard ME, Wegner RE, Reineman K, Heron DE, Kirkwood J, Burton SA, et al. Linear accelerator based stereotactic radiosurgery for melanoma brain metastases. J Cancer Res Ther 2012; 8: 215-21. doi: 10.4103/0973-1482.109393

98. Koay EJ, Leitner SF, Bethor J, Yeh Y, Settle SH, Brown PD, et al. Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma patients with brain metastasis. (Abstract) J Clin Oncol 2012; 30 (15 Suppl 1). doi: 10.1200/JCO.2012.30.15_suppl.4588

99. Lo SS, Radawski JD, Nelson A, Clarke JW, McGregor JM, Mayr NA, et al. Stereotactic radiosurgery with or without whole brain radiotherapy for patients with one to three melanoma brain metastases. J Radiat Oncol Biol Phys 2012; 1: 173-9. doi: 10.1016/j.sjro.2011.04-0026-0

100. Salvati M, Frati A, D'Elia A, Pesatori C, Piccirilli M, Pietrantonio A, et al. Single brain metastases from melanoma: remarks on a series of 84 patients. Neurosurgery 2012; 70: 211-8. doi: 10.1227/NEU.0b013e31822e816b

101. Mathew M, Tan M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 2013; 23: 191-5. doi: 10.1097/CMR.0b013e3283f6b90

102. Miller D, Zappula V, El Hidy N, Livingstone E, Schadenhorst D, Sure U, et al. Intracranial metastases of malignant melanoma and their recurrences—a clinical article. Clin Neurosurg 2013; 61: 1721-8. doi: 10.1016/j.clineuro.2013.03.019

103. Zikaukaite R, Schmidt H, Asmussen JT, Hansen G, Basthoft L. Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma. Melanoma Res 2013; 23: 21-6. doi: 10.1097/CMR.0b013e32835ae915

104. Dyer MA, Avold NO, Chen YH, Pinnell NE, Mitin T, Lee EQ, et al. The role of whole brain radiation therapy in the management of brain metastases. Radiat Oncol 2014; 9: 143. doi: 10.1186/1748-717X-9-143
123. Kaidar-Person O, Zagar TM, Deal A, Moschos SJ, Ewend MG, Sasaki-Adams D, et al. The incidence of radiation necrosis following stereotactic radiosurgery for melanoma brain metastases: the potential impact of immunotherapy. Anticancer Drugs 2017; 28: 669-75. doi: 10.1097/\textit{CAD}.0000000000000407

124. Minniti G, Paolini S, D’Andrea G, Lanzetta G, Cicone F, Confalonieri V, et al. Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases. J Neurooncol 2017; 132: 455-62. doi: 10.1007/s11060-017-2394-z

125. Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, et al. Iplimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 2017; 40: 444-50. doi: 10.1097/COC.0000000000001199

126. Pessina F, Navaria P, Tomatis S, Cozzi L, Franzese C, Di Guardo L, et al. Outcome evaluation of patients with limited brain metastasis from malignant melanoma, treated with surgery, radiation therapy, and targeted therapy. World Neurosurg 2017; 105: 184-90. doi: 10.1016/j.wneu.2017.05.131

127. Sperduto PW, Jiang W, Brown PO, Braunstein S, Sneed P, Watson DJ, et al. The prognostic value of BRAF, C-KIT, and NRAS mutations in melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys 2017; 98: 1069-77. doi: 10.1016/j.ijrobp.2017.03.030

128. Xu Z, Lee CC, Ramesh A, Mueller AC, Law ND, Schlesinger D, Cohen-Inbar O, et al. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. J Neurosurg 2017; 126: 726-34. doi: 10.3171/2016.2.JNS1633

129. Diao K, Bian SX, Routman DM, Yu C, Kim PE, Wagle NA, et al. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects. J Neurosurg 2018; 129: 1397-406. doi: 10.3171/2017.7.JNS171286

130. Diao K, Bian SX, Routman DM, Yu C, Ye JC, Wagle NA, et al. Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. J Neurooncol 2018; 139: 421-9. doi: 10.1007/s11060-018-2880-y

131. Fang P, Boehling NS, Koay EJ, Buchelt AD, Jakob JA, Settle SH, et al. Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. J Neurooncol 2018; 137: 67-75. doi: 10.1007/s11060-017-2695-2

132. Gabani P, Fischer-Valuck BW, Johansen TM, Hernandez-Aya LF, Keller JW, Rich KM, et al. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: patterns of care and treatment outcomes. Radiother Oncol 2018; 128: 266-73. doi: 10.1016/j.radonc.2018.06.017

133. Kano H, Morales-Restrepo A, Iyer A, Weiner GM, Mousavi SH, Kirkwood JM, et al. Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery. J Neurosurg 2018; 128: 14-22. doi: 10.3171/2016.6.JNS161011

134. Kotecha R, Miller JA, Venur VA, Mohammadi AM, Chao ST, Suh JH, et al. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. J Neurosurg 2018; 129: 50-9. doi: 10.3171/2017.1.JNS162797

135. Ladwa R, Atkinson V. The changing paradigm of management in melanoma brain metastases. Asia Pac J Clin Oncol 2018; 14: 453-8. doi: 10.1111/ajoc.12998

136. Matsunaga S, Shuto T, Yamamoto M, Yomo S, Kondo T, Kobayashi T, et al. Gamma Knife radiosurgery for metastatic brain tumors from malignant melanomas: a Japanese multi-institutional cooperative and retrospective cohort study. JLGK1501. Stereotact Funct Neurosurg 2018; 96: 162-71. doi: 10.1159/000488948

137. Tio M, Wang X, Carlino MS, Shivilingam B, Fogarty GB, Guminski AD, et al. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell Melanoma Res 2018; 31: 509-15. doi: 10.1111/pccr.12682

138. Zubatkina I, Ivanov P. Early imaging radiore sponsiveness of melanoma brain metastases as a predictor of patient prognosis. J Neurosurg 2018; 129: 354-65. doi: 10.3171/2017.1.JNS162075

139. Jardim A, Scott J, Drew Z, Foote MC, Sadasivan AP, Hall B, et al. Extent of surrounding edema does not correlate with acute complications after radiosurgery for melanoma brain metastases. Neurooncol 2019; 145: 581-5. doi: 10.1093/neuonc/nyz030-9

140. Mastorakos P, Xu Z, Yu J, Hess J, Qian J, Chatrath A, et al. BRAF V600 mutation and BRAF kinase inhibitors in conjunction with Stereotactic radiosurgery for intracranial melanoma metastases: a multicenter retrospective study. Neurosurgery 2019; 84: 868-80. doi: 10.1093/neuros/nyz020

141. Tjung MC, Moraes FY, Shultz D. Intracranial control and radionecrosis in melanoma patients with brain metastases treated with stereotactic radiosurgery. Radiat Oncol 2019; 144-9. doi: 10.1016/j.jocn.2019.12.063

142. McDougall F, Kow CY, Falcke A, Heppner P, Law A, Bok A, et al. Metastatic melanoma: surgical treatment of brain metastases - Analysis of 110 patients. J Clin Neurosci 2020; 73: 144-9. doi: 10.1016/j.jocn.2019.12.063